Latham & Watkins Represents Amgen in US$4 Billion Senior Unsecured Notes Offerings
Amgen Inc., one of the world’s leading biotechnology companies, priced on February 17, 2022, a senior unsecured notes offerings consisting of US$750,000,000 3.000% Senior Notes due 2029, US$1,000,000,000 3.350% Senior Notes due 2032, US$1,000,000,000 4.200% Senior Notes due 2052, and US$1,250,000,000 4.400% Senior Notes due 2062. The 3.000% Senior Notes due 2029 were Amgen’s inaugural offering of “green bonds,” the proceeds of which will be used for eligible green projects.
Latham & Watkins LLP represents Amgen in the offerings with a corporate deal team led by Orange County/New York partner Charles Ruck, New York/Los Angeles partner Greg Rodgers, and Washington, D.C. counsel Chuck Cassidy, with New York associates Matt DeSilva, Carolina Bernal, and Daphne Lambadariou. Advice was also provided on intellectual property matters by Los Angeles partner Ghaith Mahmood and Los Angeles counsel Hui (Jia Jia) Huang, with Los Angeles associate Heather Lui; on regulatory matters by Washington, D.C. partners Chris Schott and Ben Haas and San Diego/Washington, D.C. counsel Amy Speros, with San Diego associate Kiera Murphy; on tax matters by New York partners Jiyeon Lee-Lim and Jocelyn Noll, with New York associates Aaron Bernstein and Michael Syku; on litigation matters by Orange County partner Michele Johnson, with Orange County associate Sonya Shaikh; and on ESG matters by New York partner Betty Huber.